Perrin Wilson, Ph.D.
Chief Business Officer
Perrin brings to Climb Bio over 17 years of experience in the pharmaceutical and biotech industry. Prior to Climb Bio, she served as Senior Vice President, Business Development and Strategy at Nuvalent and held positions of increasing responsibility at Forma Therapeutics/Novo Nordisk, including Head of Forma Business Development and Integration Management Office, Vice President Business Development and Senior Director Global Marketing, Sickle Cell Disease Strategy. While at Forma, Perrin led the $1.1 billion acquisition by Novo Nordisk and out-licensing of Forma’s oncology portfolio and was responsible for developing the global brand plan and supporting the ex-US and lifecycle management strategy for the sickle cell program. Before that, she spent seven years at Takeda in various business development and commercial roles leading multiple transactions to strengthen Takeda’s oncology pipeline, including the $5.2 billion acquisition of ARIAD, and leading the global strategy and pre-launch preparations for Takeda’s myelodysplastic syndromes program. Earlier in her career, she spent seven years at Forest Laboratories, Inc. in both business development and commercial roles.
Dr. Wilson received her B.Sc. from Lafayette College and Ph.D. from The Rockefeller University.
Every mountain top is within reach if you just keep climbing – Barry Finlay